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Fibrosis across different organs and tissues is likely to share common pathophysiological mechanisms 
and pathways. Recently, a polymorphism (rs12979860) near the interferon lambda gene (IFNL3) was 
shown to be associated with fibrosis in liver across multiple disease etiologies. We determined whether 
this variant is a risk factor for pulmonary fibrosis (PF) and worsening cutaneous fibrosis in systemic 
sclerosis (SSc). Caucasian patients with SSc (n = 733) were genotyped to test for association with the 
presence of PF and worsening of skin fibrosis. Serum IFN-λ3 levels from 200 SSc cases were evaluated. 
An association of the IFNL3 polymorphism with PF was demonstrated (OR: 1.66 (95% CI: 1.142–2.416, 
p = 0.008). The IFNL3 variant was not a risk factor for worsening of skin fibrosis. Functionally, IFN-
λ3 serum levels were higher among subjects with PF compared to those unaffected (P < 0.0001). In 
conclusion, IFNL3 serum levels and the genetic variant known to be associated with liver fibrosis are 
similarly linked to PF, but not to worsening of skin fibrosis in SSc. These data highlight both common 
fibrosis pathways operating between organs, as well as differential effects within the same disease.
Despite contributing up to 45% of deaths in the developed world, fibrotic diseases have largely been overlooked 
from the perspective of a shared phenotype1. In this regard, organs such as lung, liver, skin, and kidney, while pos-
sessing unique tissue-specific fibrosis features, are likely to share common core and regulatory pathways. Hence, 
a multi-organ approach was recently suggested to identify druggable targets for generic anti-fibrotic therapies1.
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Systemic sclerosis (scleroderma, SSc) is a complex autoimmune disease characterized by fibrosis in skin and 
internal organs, immune dysregulation, and vasculopathy that is associated with a high morbidity and mortality. 
A hallmark of SSc is clinical and inter-individual heterogeneity2. Though the pathogenesis of SSc remains poorly 
understood, there is accumulating evidence suggesting that at least in part, genetic factors are involved2.
Pulmonary fibrosis (PF) (interstitial lung disease; ILD) is a leading cause of morbidity and mortality in 
patients with SSc3. As new treatments become available or are developed for SSc-associated PF and other forms of 
PF, early identification of high-risk patients is paramount for early intervention and through this, improved clin-
ical outcomes3. Unfortunately, reliable predictors of who will develop PF among those with scleroderma are not 
available. Genetic variants that might contribute to more severe fibrosis and/or progression could fill this need, as 
they do not fluctuate over the course of disease and are not time-dependent. Hence these variants are attractive 
candidates for the development of biomarkers predictive of progression and for risk stratification. The latter is 
also pivotal for personalization of therapy, and for improving clinical trial design for new therapies2.
We and others recently reported that single nucleotide polymorphisms (SNPs) in the interferon lambda 
(IFNL, a type III interferon) 3 region originally discovered through genome-wide association studies (GWAS) as 
a predictor of hepatitis C virus (HCV) clearance, are a strong predictor of the risk for fibrosis risk across multiple 
liver diseases4–6. IFNL receptors have restricted expression to epithelial tissues including lung and liver and thus 
respond to type III IFNs7. Thus, it is plausible that genetic variants in the IFNL3 locus could also affect PF risk. 
A key difference between idiopathic pulmonary fibrosis (IPF) and SSc-associated PF is the role of inflammation. 
Inflammation is thought to play a role in SSc-associated PF2 but this remains less clear for IPF. In this study, we 
evaluated whether there is a link between IFNL3 variants and the risk of skin and pulmonary fibrosis in a large 
cohort of Caucasian patients with SSc. Functionally, IFNλ-3 levels according to lung fibrosis were also evaluated 
in human and mice.
Results
Patient characteristics. Supplementary Table 1 summarises the main features of the cohort. A total of 
733 patients were eligible, of whom 24.5% had PF. Genotyping was successful for all samples except three. The 
genotype distribution of IFNL3 rs12979860 conformed to Hardy-Weinberg equilibrium and the minor allele 
frequency (MAF) was 0.316, similar to that observed in a healthy Caucasian population from the 1000 genome 
project (http://browser.1000genomes.org). Hence, suggestive that IFNL3 rs12979860 is not associated with SSc 
susceptibility.
IFNL3 rs12979860 and pulmonary fibrosis. The major IFNL3 rs12979860 CC genotype previously asso-
ciated with liver fibrosis was present at a significantly higher frequency in SSc patients with pulmonary fibrosis 
compared to those without (29% vs 21%, OR: 1.51 (95% CI: 1.077–2.119, p = 0.01). In multiple logistic regression 
analysis adjusting for age, gender, baseline disease duration and baseline modified Rodnan skin thickness score 
(mRSS), IFNL3 rs12979860 CC genotype remained independently associated with the risk of PF (OR: 1.66 (95% 
CI: 1.142–2.416, p = 0.008). No difference in disease duration was observed between subjects with and without 
PF or according to IFNL3 genotype (9.46 (3.2–17.36) vs 8.63 (2.46–18.45), p = 0.6 and (6.7 (1.93–17.6) vs 7.34 
(1.72–14.09), p = 0.9) in subjects with CC and CT/TT genotype, respectively.
IFNL3 rs12979860 and worsening of skin fibrosis. Next, we evaluated the association of IFNL3 
rs12979860 with worsening of skin fibrosis within ~1 year of study enrolment (follow-up time of 1.07 (0.99–1.36) 
years). In the overall cohort (only 632 patients had follow-up mRSS recorded). There was no significant associa-
tion between rs12979860 genotype and worsening of skin fibrosis within 1 year (OR: 0.938, 95% CI: 0.543–1.619, 
p = 0.8). A similar result was obtained when a Cox proportional-hazards regression model was applied after adjust-
ment for age, sex and baseline disease duration (adjusted HR for time to mRSS > 5: 0.934, 95% CI: 0.458–1.591, 
p = 0.8). In three further analyses, we considered only subjects with mRSS ≥ 7 (n = 316) at first visit. This cut-off 
was chosen based on previous reports8, that it represents the lowest value required to be considered as diffuse cuta-
neous systemic sclerosis (dcSSc). In this analysis, rs12979860 had no impact on the risk of worsening of skin fibro-
sis (OR: 1.13, 95% CI: 0.505–2.531, p = 0.7). In the second analysis conducted in subjects with diffuse SSc (n = 155), 
rs12979860 again demonstrated no association with the risk of worsening of skin fibrosis. Finally, in a third analysis 
restricted to subjects with early disease (that is, baseline disease duration shorter than 5 years) (n = 179), IFNL3 
rs12979860 was again not associated with the extent of skin involvement (diffuse vs. limited) or baseline mRSS. No 
association was observed between IFNL3 genotype and autoantibody status, namely anti-topoisomerase antibody 
(anti-Scl-70), anti-centromere antibodies or anti-RNA polymerase III (data not shown).
Serum IFN-λ3 levels. We recently showed that IFN-λ3 but not IFN-λ4 mediates the IFNL3/IFNL4 haplo-
type dependent association with liver inflammation and fibrosis9. Hence, to further explore the functional rele-
vance of rs12979860, we evaluated serum IFNλ-3 levels in 200 cases with SSc. As expected and consistent with 
our hypothesis, IFN-λ3 protein levels were 10 times as high among subjects with PF as among those unaffected 
by PF (P < 0.0001) (Fig. 1). Importantly, this difference remained significant even after stratification according 
to rs12979860 genotype (Supplementary Figure 1). Subjects who were homozygous for the major allele have 
higher serum IFN-λ3 levels compared to those carrying at least one copy of the minor allele in the entire ELISA 
sub-cohort (median 23.48 (4.28–77.5) vs. 18.35 (4.44–68.3), p = 0.2) and after stratification according to patients 
with and without pulmonary fibrosis), but this was not significant (Supplementary Figure 2). Notably, 62 (31%) of 
these patients received one or more immunosuppressive agents. Thus, we examined whether immunosuppressive 
agents have any effect on IFN-λ3 levels. In this analysis, there was no association between use of immunosup-
pressive drugs and serum IFN-λ3 levels (median 23.84 (4.29–70.26) vs. 14.2 (4.32–78), p = ns) or between type 
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of immunosuppressive agent when assessed separately. The association between PF and IFN-λ3 levels remained 
significant after adjusting for the use of immunosuppressive agents (OR = 1.01, 95% CI: 1.004–1.015, p = 0.0001).
Ifnl3 expression in bleomycin-induced pulmonary fibrosis. To further investigate the role of IFNL3 
in lung fibrosis, we examined Ifnl3 mRNA expression in mice with lung fibrosis induced by bleomycin using 
ddPCR. Consistent with the human data, Ifnl3 mRNA expression in bleomycin treated mice was significantly 
higher than that in the control group (P < 0.05) (Fig. 2).
Discussion
In this study, we demonstrate an association of genetic variants around the IFNL3 locus with an increased risk of 
SSc-associated PF, but not with the extent or worsening of skin fibrosis. Furthermore, IFN-λ3 serum levels were 
higher in subjects with PF compared to unaffected patients, including when stratified by IFNL3 genotype and in 
the lungs of mice with bleomycin-induced pulmonary fibrosis. Collectively, our findings in concert with earlier 
reports on the risk of fibrosis across multiple liver diseases4,5, suggest that IFNL3 is a core regulatory fibrotic 
pathway.
The functional mechanisms for the IFNL3 association with fibrosis generally and PF in particular, remain 
elusive. There is mounting evidence supporting a role for IFNL in the control of inflammation in response to 
viral and bacterial infections of epithelial tissues, including of the liver, the gastrointestinal tract and lung7. Thus, 
it is conceivable that IFNL, through its contribution to tissue inflammation that is well-known to be present in 
the lungs of patients with SSc and PF2, modulates the progression of pulmonary disease. Support for a role for 
Figure 1. Quantification of IFNλ3 using a highly sensitive chemiluminescent enzyme immunoassay in human 
serum samples. The levels of IFNλ3 were measured in 200 patients with SSc by a chemiluminescent enzyme 
immunoassay relative to the presence or absence of pulmonary fibrosis (PF). The x axis shows pulmonary 
fibrosis status dichotomized as absent (n = 100) or present (n = 100). The y axis shows serum IFNλ3 levels as 
pg/mL. The number of independent samples tested in each group is shown in parentheses. Each group is shown 
as a box plot and the median values are shown as thick dark horizontal lines. The box covers the twenty-fifth 
to seventy-fifth percentiles. We tested the difference in median values among genotypes using the two-tailed 
Mann–Whitney test and plotted the box plots using Graph pad prism 7.
Figure 2. Absolute quantification of Ifnl3 mRNA by ddPCR in murine lung. Basal Ifnl3 expression was 
measured as number of copies/100 ng of total RNA in lungs of bleomycin- and saline-treated mice by ddPCR 
analysis. N = 5 mice per each group. Bars represent mean ± SEM. *P < 0.05.
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IFNL in PF can be extrapolated from other published reports. For example, a recent report showed higher serum 
IFNL1 levels in patients with SSc compared to healthy controls (11). Further, a variant in the interferon regulator 
factor-5 (IRF5) gene, a transcription factor relevant to the expression of type Ι and Ш interferons was discovered 
by GWAS as a susceptibility variant for SSc10. This was shown later to be associated with better preservation of 
lung function, milder interstitial lung involvement and longer survival11. The protective allele of this variant 
(rs4728142) results in reduced IRF5 transcript levels and presumably IFNL transcription. Consistently, attempts 
to treat patients with SSc with another IFN (IFN-α) resulted in a substantial worsening of lung disease12.
From a clinical perspective, the present findings if further independently replicated, would suggest that IFNL3 
variant testing (either alone or as part of a polygenic risk score) and subsequent risk stratification, could be part of 
the counselling of patients with SSc who develop PF. From a translational standpoint, there are ongoing efforts to 
test the safety and efficacy of IFN-α blockade, such as anti-IFN-α receptor monoclonal antibody therapy for the 
management of SSc13. However, due to the restricted expression of IFNL receptors compared to the ubiquitous 
expression of IFN-α14, IFNL blockade could be a more attractive therapeutic target, especially for SSc-associated 
lung disease.
In this study, IFNL3 genotype had no impact on the prediction of progressive skin fibrosis in the overall cohort 
or in the subset with diffuse SSc. As the ASCS cohort is not an inception cohort, the majority of subjects had long 
disease duration. Since it is well-known that skin thickening progresses more rapidly in early than late disease2, 
we are not able to totally exclude the possibility that inclusion of subjects with longer disease duration might have 
limited our ability to observe an effect of IFNL3 genotype on worsening of skin fibrosis. However, our sensitivity 
analysis in subjects with early disease duration did not show a trend for the association, which argues against this 
possibility.
The current study has strengths and limitations. The data were derived from a large well-characterised mul-
ticenter prospective cohort showing the typical features of SSc with extensive clinical data and disease char-
acteristics. Furthermore, the ASCS-derived dataset enabled analysis of worsening skin fibrosis over a median 
12 months follow-up. The latter is widely considered ideal to detect meaningful changes and is used in clinical 
trials8. Limitations of this study include the lack of a replication cohort for the positive association observed 
with PF, the number of patients with full auto-antibody profiles, and the fact that it was not an inception cohort. 
Nevertheless, the associations we observed are similar to those previously demonstrated for liver in large 
independently-replicated cohorts (>4000 and 1300 patients)4,5. Further studies will be required to address the 
impact of IFN-λ3, as well as IFNL3 genetic variation on ILD severity and progression in cohorts of incident 
patients followed prospectively with multiple HRCTs, and to clarify the functional mechanisms of this genetic 
association.
In conclusion, we demonstrate that the IFNL3 genetic variant and serum levels of IFNλ-3 are significantly 
associated with the risk of PF in a Caucasian population with SSc. The IFNL3 variant was not a risk factor 
for the worsening of skin fibrosis. Consistently, Ifnl3 mRNA expression was higher in lungs from mice with 
bleomycin-induced pulmonary fibrosis. The functional mechanisms for the pro-fibrotic effects of IFNL3 will 
require further investigation and if confirmed, can be exploited as a potentially more effective therapeutic target.
Methods
Patient cohort. The study comprised 733 consecutive Caucasian patients with SSc from the Australian 
Scleroderma Cohort Study (ASCS), a multi-center prospective study of risk factors for clinically important out-
comes in SSc. All patients fulfilled either American College of Rheumatology or Leroy and Medsger criteria for 
SSc14. The study protocol was conformed to the ethical guidelines of the 1975 Declaration of Helsinki. Each of 
the participating centres obtained approval for the study from their respective ethics committees and study was 
performed according to the recommendations of the centers involved. The ASCS compromises 13 Australian 
centres and has been approved by the human research ethics committee of each of the participating hospitals 
(St. Vincent’s Hospital, Melbourne Royal Adelaide Hospital, Monash Medical Centre, Royal Perth Hospital, 
The Queen Elizabeth Hospital, Sunshine Coast Rheumatology, Prince Charles Hospital, John Hunter Hospital, 
Royal North Shore Hospital, Royal Prince Alfred Hospital, St George Hospital, Canberra Rheumatology and 
the University of Tasmania). Written informed consent for genetic testing was obtained from all participants. 
Details of the methods for pulmonary disease assessment, skin fibrosis progression assessment, genotyping, IFN-
λ3 serum levels measurement, and the mouse model is provided in Supplementary Methods.
Statistical analysis. The Student’s t-test, Mann-Whitney test, Wilcoxon’s test and Fisher’s exact tests were 
used, as appropriate. Multiple logistic and Cox proportional-hazards regression models were fitted adjusting for 
common risk factors as covariates. The IFNL3 rs12979860 genotype was dichotomized as CC versus CT/TT, as 
previously reported4,15.
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